Poly(I:C) stimulation leads to phenotype changes in PMCs
. | % PMCs . | . | MFI . | . | ||
---|---|---|---|---|---|---|
. | – . | pIC . | – . | pIC . | ||
I-A/E | 16.6 ± 3.8 | 92.1 ± 2.2* | 944 ± 174 | 2594 ± 832† | ||
CD80 | 30.1 ± 7.9 | 92.7 ± 2.0* | 205 ± 14 | 1366 ± 208* | ||
CD28 | 3.3 ± 1.3 | 36.3 ± 9.7† | 174 ± 83 | 89 ± 60 | ||
CD21/35 | 15.8 ± 3.4 | 76.9 ± 7.1* | 56 ± 4 | 195 ± 32* | ||
FcγRII/III | ||||||
High | 80.1 ± 3.5 | 92.3 ± 2.2† | 453 ± 15 | 1391 ± 122* | ||
Intermediate | 18.1 ± 3.0 | 7.5 ± 2.2† | 150 ± 7 | 115 ± 6† |
. | % PMCs . | . | MFI . | . | ||
---|---|---|---|---|---|---|
. | – . | pIC . | – . | pIC . | ||
I-A/E | 16.6 ± 3.8 | 92.1 ± 2.2* | 944 ± 174 | 2594 ± 832† | ||
CD80 | 30.1 ± 7.9 | 92.7 ± 2.0* | 205 ± 14 | 1366 ± 208* | ||
CD28 | 3.3 ± 1.3 | 36.3 ± 9.7† | 174 ± 83 | 89 ± 60 | ||
CD21/35 | 15.8 ± 3.4 | 76.9 ± 7.1* | 56 ± 4 | 195 ± 32* | ||
FcγRII/III | ||||||
High | 80.1 ± 3.5 | 92.3 ± 2.2† | 453 ± 15 | 1391 ± 122* | ||
Intermediate | 18.1 ± 3.0 | 7.5 ± 2.2† | 150 ± 7 | 115 ± 6† |